Convective therapies with high cut-off membranes (HCO) are usually not recommended because of theoretical excessive albumin loss. The aim of this in vitro study is to demonstrate the noninferior safety of pre-dilution hemodiafiltration with HCO (HCO-CVVHDF) with isotonic citrate anticoagulation (18 mmol/L) with respect to heparin anticoagulated hemodialysis with HCO (HCO-CVVHD) in terms of albumin removal and citrate load.

Albumin Loss and Citrate Load in Pre-Dilution High Cut-Off-CVVHDF with Regional Citrate (18 mmol/L) and High Cut-Off CVVHD with Systemic Heparin: An in vitro Study / Villa, Gianluca; Neri, Mauro; De Rosa, Silvia; Samoni, Sara; Chelazzi, Cosimo; Romagnoli, Stefano; Lorenzin, Anna; de Cal, Massimo; Ronco, Claudio; De Gaudio, Angelo Raffaele. - In: BLOOD PURIFICATION. - ISSN 0253-5068. - ELETTRONICO. - 46:(2018), pp. 205-213-213. [10.1159/000490342]

Albumin Loss and Citrate Load in Pre-Dilution High Cut-Off-CVVHDF with Regional Citrate (18 mmol/L) and High Cut-Off CVVHD with Systemic Heparin: An in vitro Study

Villa, Gianluca
;
Chelazzi, Cosimo;Romagnoli, Stefano;De Gaudio, Angelo Raffaele
2018

Abstract

Convective therapies with high cut-off membranes (HCO) are usually not recommended because of theoretical excessive albumin loss. The aim of this in vitro study is to demonstrate the noninferior safety of pre-dilution hemodiafiltration with HCO (HCO-CVVHDF) with isotonic citrate anticoagulation (18 mmol/L) with respect to heparin anticoagulated hemodialysis with HCO (HCO-CVVHD) in terms of albumin removal and citrate load.
2018
46
205-213
213
Villa, Gianluca; Neri, Mauro; De Rosa, Silvia; Samoni, Sara; Chelazzi, Cosimo; Romagnoli, Stefano; Lorenzin, Anna; de Cal, Massimo; Ronco, Claudio; De...espandi
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in FLORE sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificatore per citare o creare un link a questa risorsa: https://hdl.handle.net/2158/1129988
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 4
  • ???jsp.display-item.citation.isi??? 3
social impact